Woori IO Secures NDA with Sinopharm to Enter $12B China Glucose Market
Woori IO signed an NDA with Sinopharm Beijing to share data on its noninvasive NIR glucose monitoring technology for regulatory, clinical and commercial evaluation in China. Sinopharm, with 2024 revenue near USD81 billion and China’s largest distribution network, could target 140 million diabetics in a device market projected above USD12 billion by 2032.
1. Woori IO Signs NDA with Sinopharm
On March 19, OSR Holdings’ subsidiary Woori IO finalized a mutual non-disclosure agreement with Sinopharm Group Beijing Huahong, establishing a formal framework for exchanging data on Woori IO’s noninvasive near-infrared glucose monitoring technology. This NDA opens discussions on regulatory, clinical and commercial pathways in the Chinese market.
2. Sinopharm’s Distribution Reach
Sinopharm Group Beijing Huahong, a subsidiary of state-owned Sinopharm Group, generated approximately USD81 billion in 2024 revenue and operates China’s most extensive pharmaceutical and medical device network, covering all provinces and major cities. Its scale and government ties position it as a key distribution partner for medical technologies.
3. China’s Diabetes Market Potential
China is home to over 140 million people with diabetes, making it one of the largest global diabetes markets; the country’s diabetes device segment is projected to exceed USD12 billion by 2032. Rising demand for noninvasive, pain-free monitoring solutions underpins growth opportunities for Woori IO’s technology.
4. Strategic Outlook and Next Steps
While discussions remain preliminary, OSR intends to evaluate potential regulatory filings, clinical trial design and commercialization strategies in China. The company is also exploring global multicenter trials and additional partnerships to advance its next-generation noninvasive glucose monitoring platform.